RobynMScherberMD

PubMed

• 1 citations
  Impact of gender representativeness in online symptom survey and clinical trial participation among patients with myeloproliferative neoplasms.
  Blake Langlais, Amylou C Dueck, Heidi E Kosiorek, Carolyn Mead-Harvey, Eric Meek
  Leukemia & Lymphoma. 2024-10-01
• Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF TSS or MPN-10) Q...
  Mihnea-Alexandru Găman, Robyn Marie Scherber, Iulia Ursuleac, Ana Manuela Crişan, Sorina Nicoleta Bădeliţă
  Journal of Clinical Medicine. 2024-06-02
• 1 citations
  The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence.
  Laura F Mendez Luque, Julio Avelar-Barragan, Hellen Nguyen, Jenny Nguyen, Eli M Soyfer
  Cancer Research Communications. 2024-03-05

Journal Articles

• Reducing symptom burden in patients with myeloproliferative neoplasms in the era of JAK inhibitors to improve quality of life and prognosis  
  Mesa, RA, Scherber, RM, Geyer, HL, Leuk Lymphoma, 1/1/2015
• Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development  
  Geyer,H.,Dueck, A.C., Scherber, R.M., Mesa, RA, Mediators of Inflammation, 1/1/2015
• Ruxolitinib in Clinical Practice for Therapy of Myelofibrosis: Single USA Center Experience Following FDA Approval  
  Geyer, HL, Emanuel, RM, Mesa, RA, Leukemia and Lymphoma, 1/1/2014
• Patients with polycythemia vera have the worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms  
  Abelsson J, Andreasson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, Emanuel R, Mesa R, Johansson P, Leuk Lymphoma, 1/12/2013
• Ruxolitinib as an Emerging Treatment in Myelofibrosis  
  Emanuel RM, Geyer, HL, Mesa, RM, Blood and Lymphatics Cancer, 1/1/2013
• Myelofibrosis Symptoms and Management  
  Geyer HL, Emanuel RM, Mesa RA, Myeloid & Lymphoid Disorders in Practice, 1/1/2012
• Relevance of Weight Loss, Splenomegaly, and Hypocholesterolemia in the Treatment of Myeloproliferative Neoplasms: Implications for a JAK2 Inhibitor Era  
  Scherber, R.M., Mesa, R.A., US Oncology and Hematology, 1/1/2011
• Targeting African American Non-Smokers to Motivate Smokers to Quit: A Qualitative Inquiry  
  Thomas, JL, Scherber, R., Stewart, DW, Lynam, I, Daley, C & Ahluwalia, JS, Health Education and Behavior, 1/1/2010
• Support Needs of Overweight African American Women for Weight Loss  
  Thomas, J.L., Stewart, D.W., Lynam, I.M., Daley, C.M., Befort, C.A., Scherber, R.M., Mercurio, A.E., Okuyemi, K.S. & Ahluwalia, J.S., American Journal of Health Behavior, 1/1/2009
• Knowledge and Beliefs about Smoking among Urban African Americans with Type 2 Diabetes: A Qualitative Inquiry  
  Thomas, J.L., Stewart, D.W., Makosky, C. Befort, C.A., James, A.S., Snow, P.M., Scherber, R.M., Ahluwalia, J.S., Kansas Journal of Medicine, 1/1/2009
• Indole-3-Carbinol Inhibits (4-Methylnitrosamino) -1- butanone Plus Benzo[a]pyrene-Induced Lung Tumorigenesis in A/J Mice and Modulates Carcinogen-Induced Alterations i...  
  Kassie, F., Anderson, L.B., Scherber, R., Yu, N., Lahti, D., Upadhyaya, P., & Hecht, S.S., Cancer Research, 1/1/2007
• Join now to see all

Books/Book Chapters

• Cambridge Book 
  Chapter: Incorporating Symptomatic Assessment in Therapy Choice for Patients with Myeloproliferative Neoplasms. 
  Scherber, RM, Geyer, HL, Mesa, RA2014

Abstracts/Posters

• Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
  Robyn M. Scherber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Myeloproliferative Neoplasms and Depressive Symptoms, Diagnosis, and Associations.
  Padrnos, L, Scherber, RM, Langlais, B, Dueck, AC, Huberty, J, Geyer, HL, Gowin, K, Kosiorek, H, Bruso, M, Senyak, Z, Clark, M, Boxer, M, Cotter, M, Harrison, C, ..., American Society of Hematology, Atlanta, GA, 1/1/2017
• Determining Meaningful Change in the Myelofibrosis Symptom Assessment Form (MFSAF) V2.0 using a Combination of Distribution- and Anchor-based Approaches in the COMFORT...
  Dueck AC, Scherber RM, Kosiorek H, Langlais B, Padrnos L, Palmer J, Verstovsek S, Sloan J, Geyer H, Mesa R, European Hematology Association, Madrid, Spain, 1/1/2017
• Correlations Between Inflammatory Biomarkers and Individual Symptoms Expressed by Myelofibrosis Patients in the COMFORT-I Trial: Analysis of Baseline Associations and ...
  Geyer H, Scherber RM, Kosiorek H, Verstovsek S, Langlais B, Padrnos L, Palmer J, Dueck AC, Mesa R, European Hematology Association, Madrid, Spain, 1/1/2017
• Nutrition in Myelofibrosis: Correlates from the COMFORT-1 Study.
  Scherber RM, Geyer H, Dueck AC, Johnson C, Langlais B, Padrnos L, Palmer J, Fleischman A, Mesa R, European Hematology Association, Madrid, Spain, 1/1/2017
• Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE...
  Scotch, A, Scherber, RM, Bruso, M, Kosiorek, HE, Dueck, AC, Geyer, H, Fauble, VD, Vannucchi, AM, Fuentes AK, Andersen, CL, Ejerblad, E, Birgegard, G, Johansson, P..., American Society of Hematology, Atlanta, GA, 1/1/2017
• Focus Group Study of Needs and Preferences Regarding Nutrition Among Participants with Myeloproliferative Neoplasms.
  Scherber, RM, Leproux, A, Morse, SJ, Craver, BM, Lai, Y, Dueck, A, Geyer, HL, Palmer, J, Padrnos, J, Mesa, RM, and Fleischman, AG, American Society of Hematology, Atlanta, GA, 1/1/2017
• Psychostimulant Use Among Myeloproloferative Neoplasm Patients.
  Scherber, RM, Langlais, B, Kosiorek, H, Dueck, AC, Geyer, HL,Senyak, Z, McCallister, A, Cotter, M, VanHusen, B, Palmer, J, Padrnos, L, Harrison, C, Fleischman, AF Hube..., American Society of Hematology, Atlanta, GA, 1/1/2017
• Nutrition and Supplement Use Characteristics in the Myeloproliferative Neoplasms: Results from the Nutrient Survey.
  Scherber, RM, Langlais, B, Padrnos, L, Palmer, J, Fleischman, AF, and Mesa, RA, American Society of Hematology, Atlanta, GA, 1/1/2017
• Duration Matters: Impact of Time from Diagnosis on Symptoms in Patients with Hematologic Malignancies.
  Padrnos, L, Kosiorek, H, Bennett R, Dueck, AC, Gowin, K, Scherber, RM, Geyer, HL, Palmer, P, Northfelt, D, Mikhael, J, Khera, N, and Mesa, RA, American Society of Hematology, Atlanta, GA, 1/1/2017
• Quality of Life and Symptom Burden Among Patients with Myeloproliferative Neoplasms: Do Symptoms Impact Quality of Life?
  Langlais B, Kosiorek, H, Geyer, HL, Scherber, RM, Mesa, RA, Dueck, AC, American Society of Hematology, Atlanta, GA, 1/1/2017
• Sleep and Psychiatric Disturbance in Chronic Philadelphia Negative Myeloproliferative Neoplasms.
  Gowin, K, Langlais B, Kosiorek, HE, Dueck, A, Millstine, D, Huberty, J, Eckert, R, Padrnos, L, Scherber, RM and Mesa RA, American Society of Hematology, Atlanta, GA, 1/1/2017
• Nutritional Needs and Preferences of Myeloproliferative Neoplasm Patients: Phase IA of the NUTRIENT Study.
  Scherber RM, Geyer H, Dueck AC, Johnson C, Langlais B, Padrnos L, Palmer J, Fleischman A, Mesa R, European Hematology Association, Madrid, Spain, 1/1/2017
• Quality of Life Independently Predicts Overall Survival in the Myelofibrosis: Key Insights from the COMFORT-1 Study.
  Scherber RM, Kosoriek H, Geyer H, Verstovsek S, Sloan J, Langlais B, Padrnos L, Palmer J, Fleischman A, Dueck AC,Mesa R, European Hematology Association, Madrid, Spain, 1/1/2017
• Myeloproliferative Neoplasm Symptom Burden and Quality of life: Evidence of Significant Impairment Compared to Controls.
  Anderson LA, James G, Duncombe AS, Mesa RA, Scherber RM, Dueck AC, deVocht F, Clarke M, McMullin M, Hematology Association Ireland Meeting, Athlone, Ireland, 1/1/2016
• Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Ess...
  Harrison C, Mead A, Panchal A, YapC, Houlton A, Aliman S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltisis N, Knapper S, Ali S, Hamblin A, Scherber R, Geyer H, Scotch..., American Society of Hematology, San Diego, CA, 1/1/2016
• Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group.
  Scherber, RM, Geyer, H, Dueck, AC, et. al, American Society of Hematology, San Diego, CA, 1/1/2016
• Symptoms, Risk Classification, and Spleen Size in JAK2 Inhibitor-naïve Myelofibrosis: Implications for JAK2 Inhibitor Treatment.
  Scherber, RM, Geyer, H, Dueck, AC, Mesa, RA, European Hematology Association, Copenhagen, Denmark, 1/1/2016
• Impact of splenomegaly on MPN symptoms and association with clinical features: An analysis of the MPN QOL International Study Group.
  Geyer H, Scherber R, Kosiorek J, Dueck A, Kiladjian JJ, Slot S, Mesa RA, European Hematology Association, Copenhagen, Denmark, 1/1/2016
• Ruxolitinib compared to best avavilable therapy for essential thrombocythemia patients resistant or intoleratnt to hyroxycarbamide in MAJIC- An investigator lead rando...
  Harrison C, Mead A, Panchal A, Fox S, Yap C, Houlton A, Aliman S, Wood M, Chen F, Coppell J, Panoskaltsis N, Scherber R, Geyer H, Dueck A, Mesa R, McMullin MF, European Hematology Association, Copenhagen, Denmark, 1/1/2016
• Development of an MF patient reported outcome tool for FDA Qualification: Comprehensive literature search and physician cognitive debriefing results.
  Geyer H, Kosiorek H, Dueck A, Slot S, Zweegman S, Kiladjian JJ, Boekhorst P, Schouten J, Sackmann F, Fuentes A, Scherber R, Mesa RA, European Hematology Association, Copenhagen, Denmark, 1/1/2016
• Quality of Life in Patients with Myeloproliferative Neoplasms Compared to Normal Individuals- Case control Evidence of Significant Impairment.
  Duncombe, A. Titmarsh G., McMullin MF, Mesa, RA., Scherber RM, Dueck, A., De Vocht, F., Fritschi, L., Clarke, M., Anderson, LA, European Hematology Association Conference, Vienna, Austria, 1/1/2015
• Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs.
  Geyer, HM, Scherber, RM, Dueck AC, Mesa, RM, American Society of Hematology, Orlando, FL, 1/1/2015
• Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs).
  Geyer, HM, Scherber, RM, Mesa, RM, American Society of Hematology, Orlando, FL, 1/1/2015
• Myeloproliferative Neoplasm Patient Symptom Burden and Quality of Life: Evidence of significant impairment compared to controls.
  Scherber, RM, Dueck, AC, Geyer, HL, Mesa, RM, American Society of Hematology, Orlando, FL, 1/1/2015
• Join now to see all

Lectures

• A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Symptom Burden and Fatigue in MPNs: Insights into Gender Differences and Non-pharmacologic Treatments. 
  Beverly Hills, CA - 1/29/2017
• MPN related symptoms and quality of life. 
  University of California, Irvine, Irvine, CA - 1/27/2017
• MPN Casebook 3: Initial Treatment Choices in MF, Risk Models and Symptom Burden. 
  Atlanta, GA - 1/18/2017
• The NUTRIENT Trial: Nutritional Needs and Preferences of Myeloproliferative Neoplasm Patients. 
  Atlanta, GA - 1/13/2017
• Symptom and Side-Effects Management: Fatigue and Chemo Brain. 
  Anaheim, CA - 1/4/2017
• Nutritional Needs and Preferences of Myeloproliferative Neoplasm Patients: The NUTRIENT Study. 
  Times Square, NY - 1/2/2017
• 2017 Update in Myeloproliferative Neoplasms. 
  Oregon Health and Science University, Portland, OR - 1/1/2017
• Setting and attaining appropriate treatment goals in polycythemia vera. 
  1/30/2016
• The importance of symptomatic assessment to optimal MPN patient management. 
  1/29/2016
• Ruxolitinib Uses and Management. 
  Seoul, South Korea - 1/28/2016
• Optimizing the management of polycythemia vera throughout the patient journey. 
  Taipei, Taiwan - 1/1/2016
• The role of ruxolitinib in the management of myelofibrosis. 
  Taipei, Taiwan - 1/1/2016
• Current and Emerging Therapy in Myelofibrosis. 
  Houston, TX - 1/1/2016
• Navigating your MPN Symptom Burden. 
  Bethesda, MD - 1/1/2016
• Practical aspects of symptom assessment in Myeloproliferative Neoplasms. 
  Milan, Italy - 1/1/2014
• Cognitive Enhancement Drug Use Among Medical Students. 
  Scottsdale, AZ - 1/1/2014
• Fatigue Among the Myeloproliferative Neoplasms 
  Scottsdale, AZ - 1/1/2014
• Join now to see all